Diagnostic accuracy of CD4 cell count increase for virologic response after initiating highly active antiretroviral therapy
暂无分享,去创建一个
B. Strom | R. Gross | I. Frank | D. Dickinson | H. Friedman | S. Bellamy | J. Strom | G. Bisson | R. Weinstein | T. Gaolathe | N. Ndwapi | Caitlin K. Rollins | Ndwapi Ndwapi
[1] N. Ford,et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment , 2006, The Lancet.
[2] L. Myer,et al. CD4 cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa , 2006, BMC infectious diseases.
[3] A. Evans,et al. Translating Clinical Research into Clinical Practice: Impact of Using Prediction Rules To Make Decisions , 2006, Annals of Internal Medicine.
[4] Kara Wools-Kaloustian,et al. Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya , 2006, AIDS.
[5] R. Greenblatt,et al. Genotypic Resistance and Immunologic Outcomes Among HIV-1-Infected Women With Viral Failure , 2006, Journal of acquired immune deficiency syndromes.
[6] L. Myer,et al. Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design , 2005, AIDS.
[7] P. Wright,et al. Antiretroviral therapy in a thousand patients with AIDS in Haiti. , 2005, The New England journal of medicine.
[8] I. Thior,et al. Initial Response to Highly Active Antiretroviral Therapy in HIV-1C-Infected Adults in a Public Sector Treatment Program in Botswana , 2005, Journal of acquired immune deficiency syndromes.
[9] M. Egger,et al. Response to Highly Active Antiretroviral Therapy at 6 Months and Long-Term Disease Progression in HIV-1 Infection , 2005, Journal of acquired immune deficiency syndromes.
[10] J. Simon,et al. Hard choices: rationing antiretroviral therapy for HIV/AIDS in Africa , 2005, The Lancet.
[11] M. Peeters,et al. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial , 2004, The Lancet.
[12] G. Maartens,et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa , 2004, AIDS.
[13] D. Richman,et al. Baseline Predictors of CD4 T‐Lymphocyte Recovery With Combination Antiretroviral Therapy , 2002, Journal of acquired immune deficiency syndromes.
[14] D. Cooper,et al. The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy , 2002, AIDS.
[15] H. Fleury,et al. Predictors of long-term increase in CD4(+) cell counts in human immunodeficiency virus-infected patients receiving a protease inhibitor-containing antiretroviral regimen. , 2002, The Journal of infectious diseases.
[16] F. Maggiolo,et al. Discordant immunological response in HIV-positive patients on non-nucleoside reverse transcriptase inhibitor-based regimens. , 2002, AIDS (London).
[17] D. Redelmeier,et al. Prognostic indices in clinical practice. , 2001, JAMA.
[18] J. Margolick,et al. Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study , 2001, AIDS.
[19] Mardge H. Cohen,et al. The relationship between virus load response to highly active antiretroviral therapy and change in CD4 cell counts: A report from the Women's interagency HIV study. , 2000, The Journal of infectious diseases.
[20] B. Yip,et al. Full suppression of viral load is needed to achieve an optimal CD4 cell count response among patients on triple drug antiretroviral therapy , 2000, AIDS.
[21] G H Guyatt,et al. Users' guides to the medical literature: XXII: how to use articles about clinical decision rules. Evidence-Based Medicine Working Group. , 2000, JAMA.
[22] L. Jagodzinski,et al. Use of Calibrated Viral Load Standards for Group M Subtypes of Human Immunodeficiency Virus Type 1 To Assess the Performance of Viral RNA Quantitation Tests , 2000, Journal of Clinical Microbiology.
[23] M. Holodniy. Viral load monitoring in HIV Infection , 1999, Current infectious disease reports.
[24] M. Kazatchkine,et al. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease , 1998, AIDS.
[25] Amalio Telenti,et al. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART) , 1998, The Lancet.
[26] I. Stiell,et al. Implementation of the Ottawa Knee Rule for the use of radiography in acute knee injuries. , 1997, JAMA.
[27] M. Hughes,et al. Monitoring Plasma HIV-1 RNA Levels in Addition to CD4+ Lymphocyte Count Improves Assessment of Antiretroviral Therapeutic Response , 1997, Annals of Internal Medicine.
[28] S. Hammer. Advances in antiretroviral therapy and viral load monitoring. , 1996, AIDS.
[29] B. Efron. Estimating the Error Rate of a Prediction Rule: Improvement on Cross-Validation , 1983 .
[30] C. Dolea,et al. World Health Organization , 1949, International Organization.
[31] C.G.A. Mcgregor. Progress on Global Access to HIV Antiretroviral Therapy , 2006 .
[32] James Curran,et al. Scaling Up Antiretroviral Therapy in Resource-Limited Settings: Treatment Guidelines for a Public Health Approach , 2005 .
[33] V. Stone,et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.